Navigation Links
Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Date:7/8/2009

ng statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of Zyflo CR(R) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obt
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
7. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
10. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
11. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... Global HIV Infection Drug Market and ... Reportstack. The rate of HIV infection and the number of ... at a positive rate across the globe. It has been ... 2005 to 1.5 in 2013, with the rates for children ... changes in the infection rates has been the improved access ...
(Date:8/18/2014)... China is increasingly being recognized ... research industry. Clinicaltrial.gov statistics highlight the popularity of ... population; a high increase in infectious diseases; a ... pool of patients and a track record of ... China also presents challenges for the clinical research ...
(Date:8/16/2014)... Madison, Virginia (PRWEB) August 16, 2014 ... of NDA Partners LLC announced today that Agnes ... Premier Expert consultant. NDA Partners Premier Experts are ... enable them to bring extraordinary value to the ... implement critical solutions to help clients successfully develop ...
(Date:8/15/2014)... DUBLIN , Aug. 15, 2014 Research ... "Global non-GMO Food Market 2014-2018" report to their offering. ... stands for genetically modified organism, in this the scientist conducts ... genes from the DNA of an organism, such as a ... of the plant they want to alter or make genetic ...
Breaking Biology Technology:Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Former GlaxoSmithKline Senior Executive Agnes Westelinck Joins NDA Partners as a Premier Expert Consultant 2Global non-GMO Food Market 2014-2018: Key Vendors are Amy's Kitchen, Nature's Path, Organic Valley and The Hain Celestial 2Global non-GMO Food Market 2014-2018: Key Vendors are Amy's Kitchen, Nature's Path, Organic Valley and The Hain Celestial 3
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... showed remarkable immune responses in monkeys, following similarly strong, ... data from earlier animal studies. The data was presented ...
... the term "splitsville" usually means "check your prenup." ... from boron nitride nanotubes, "splitsville" could mean "happily ... National Laboratory (Berkeley Lab) and the University of ... University, have developed a technique in which boron ...
... HAYWARD, Calif., June 28, 2011 Intarcia Therapeutics, ... results of a phase 2 clinical study of ... for the treatment of type 2 diabetes at ... San Diego, California. (Logo:   http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO ...
Cached Biology Technology:Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 2Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 3Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 4Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 5Inovio Pharmaceuticals' Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial 6Splitsville for boron nitride nanotubes 2Splitsville for boron nitride nanotubes 3Splitsville for boron nitride nanotubes 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 2Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 3Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 4Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions 5
(Date:8/19/2014)... the seas during warm phases and became extinct during ... establishes a link between marine crocodilian diversity and the ... than 140 million years. , The research, led ... France and formerly from the University of Bristol, UK ... Today, crocodiles are ,cold-blooded, animals that mainly live in ...
(Date:8/19/2014)... ever had a glass of fizzy soda knows that ... in a finding with wide industrial applications, Princeton researchers ... down into the liquid as well. , "It is ... we were surprised, and fascinated, to discover that when ... injected tiny oil droplets into the water," said Howard ...
(Date:8/19/2014)... Rochelle, August 19, 2014A new ovoid structure discovered in ... clay, contains a variety of minerals, and shows evidence ... resulting melting of the permafrost and mixing of surface ... broad range of analytical studies to determine the origin ... for how this ovoid formed, point to the most ...
Breaking Biology News(10 mins):Evolution of marine crocodilians constrained by ocean temperatures 2Bubbling down: Discovery suggests surprising uses for common bubbles 2Bubbling down: Discovery suggests surprising uses for common bubbles 3Life on Mars? Implications of a newly discovered mineral-rich structure 2
... Doha, Qatar Urgent law enforcement action by governments ... crucial to addressing the illicit ivory trade, according to ... Detailed regional summaries of the data held in ... database on ivory seizures, highlight the failure of law ...
... ever before of how much radiation reaches sensitive tissues ... models of the human body being developed at the ... of computer simulation tools and 3-D patient models that ... said Wesley E. Bolch, Ph.D., a professor in the ...
... monster movies, but palaeontologists have discovered evidence of how an ... place 4 million years ago. Such fossil evidence ... of bite marks on an otherwise well-preserved dolphin skeleton, the ... that led to the death of the dolphin, and determined ...
Cached Biology News:New analysis points to ivory enforcement failures in parts of Africa, Asia 2Age, gender can affect risk to radiation treatment 2Age, gender can affect risk to radiation treatment 3Jaws -- 4 million BC 2
SpectroQuest single beam 4nm UV/Vis spectrophotometer; stand-alone unit; large angled LCD screen; large sample compartment...
Fluorescence Preserving Media, 100 mL...
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... development to targets including proteins and to ... cancer-specific surface antigens. A&Gs service is ... in approximately 40 days (duration may vary ... Phase I: Immunization, test bleed and ...
Biology Products: